Evidence map›Paper›PMID 31411779›Full record

ArticleStatistics in medicine2019

Mediation analysis of time-to-event endpoints accounting for repeatedly measured mediators subject to time-varying confounding.

Stijn Vansteelandt, Martin Linder, Sjouke Vandenberghe, Johan Steen, Jesper Madsen

Full text read
In one paragraph

Article in Statistics in medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Practical challenges in mediation analysis: a guide for applied researchers.Health services & outcomes research methodology · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Stijn VansteelandtDepartment of Applied Mathematics, Computer Science and Statistics, Ghent University, Ghent, Belgium.ORCID 0000-0002-4207-8733
Martin LinderNovo Nordisk, Bagsvaerd, Denmark.
Sjouke VandenbergheDepartment of Applied Mathematics, Computer Science and Statistics, Ghent University, Ghent, Belgium.
Johan SteenGhent University Hospital, Ghent, Belgium.
Jesper MadsenNovo Nordisk, Bagsvaerd, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this article, we will present statistical methods to assess to what extent the effect of a randomised treatment (versus control) on a time-to-event endpoint might be explained by the effect of treatment on a mediator of interest, a variable that is measured longitudinally at planned visits throughout the trial. In particular, we will show how to identify and infer the path-specific effect of treatment on the event time via the repeatedly measured mediator levels. The considered proposal addresses complications due to patients dying before the mediator is assessed, due to the mediator being repeatedly measured, and due to posttreatment confounding of the effect of the mediator by other mediators. We illustrate the method by an application to data from the LEADER cardiovascular outcomes trial.

Indexed as

Models, StatisticalRandomized Controlled Trials as TopicCardiovascular DiseasesConfounding Factors, EpidemiologicDiabetes Mellitus, Type 2Diabetic AngiopathiesEffect Modifier, EpidemiologicEndpoint DeterminationHumansHypoglycemic AgentsLiraglutideResearch DesignHypoglycemic AgentsLiraglutideg-formulalongitudinal datamediationpath-specific effecttime-dependent confounding

Identifiers

PMID31411779
PMCPMC6852414

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.